ABSTRACT
INTRODUCTION
Tumor necrosis factor-alpha (TNF-α), produced by activated macrophages, T cells and several other cell types, is a cytokine that mediates a wide range of biologic activities including the induction of tumor necrosis (Wu et al., 2006; Balkwill, 2009) . In many experimental and human cancers, TNF-α is an important component of the interplay between tumor cells and tumor stromal cells (Blankenstein et al., 1991; Qin et al., 1993; Mocellin et al., 2005; Qin et al., 2007; . The TNF-α activity has been reported to be closely associated with the disease progress in most patients with cancers as diverse as prostate cancer, breast cancer, renal cell cancer, non-small cell lung cancer, and other tumor types (Balkwill, 2009) . Fibrosarcoma is a cancerous tumor derived from fi brous connective tissue and composed of proliferating fi broblasts. This type of malignant cancer most commonly affects the limbs and the trunk of the body, but it can also invade other tissues (Coffi n and Alaggio, 2012) . The role of TNF-α in fi brosarcoma has not been completely defi ned.
TNF-α has two cell surface receptors: TNFR-1 and TNFR-2 (Balkwill, 2006) . TNFR-1 is a 55-kDa protein which presents a death domain on its intracellular region. It is expressed by almost all cell types and is the major signaling receptor for TNF-α (Cabal-Hierro and Lazo, 2012) . Studies showed that a huge majority of m yeloma cell lines failed to show TNFR-1 expression (Rauert et al., 2011) ; impaired TNFR-1 signaling pathway was associated with prostate cancer progression (Wang et al., 2009) ; infrequent presence of TNFR-1 was observed in ovarian carcinoma effusions in patients (Dong et al., 2008) ; and a high TNFR-1 expression in Dukes' stage C colorectal cancer could be a favorable indicator of prognosis (Yoshimura et al., 2003) . All these indicate that TNFR-1 may play a crucial role in tumor development. It is also reported that an up-regulation of TNFR-1 was found in the tumor biopsies of cancer patients after treatment (van Horssen et al., 2006) . Thus, it is important to clarify the possible relations of TNFR-1 expression on fi brosarcoma and their sensitivity to clinical treatment, such as chemotherapy.
The specifi c outcome of TNFR-1 signaling pathway is tumor type-dependent (Balkwill, 2006 (Balkwill, , 2009 . It is reported that TNF-α activation of TNFR-1 stimulates both pro-and anti-apoptotic & ( Fig. 2A) . Subsequently, we examined TNFR-1 expression on the cell surface by western blot and fl ow cytometry. Consistent with the previous observation, TNFR-1 was detected only on FB61-R1 cells, but not on FB61-m cells ( Fig. 2B and 2C ). The extracellular domain of TNFR-1 also exists as a soluble molecule formed via shedding from the cell surface (Levine, 2008) . As shown in Fig. 2D , the soluble TNFR-1 expression level in the supernatant of FB61-m can b arely be detected, while it reached 58 pg/mL in the FB61-R1 group. What is more, TNFR-1 on the surface of FB61-R1 cells was functional because exposure of these cells to TNF-α effi ciently up-regulated their major histocompatibility complex (MHC) class I expression (Fig. 2E) . However, TNF-α did not change the expression of MHC class I molecules on FB61-m cells, as determined by culsignaling pathways (Edelblum et al., 2008; Cabal-Hierro and Lazo, 2012) . TNFR-1 is able to induce the extrinsic apoptosis signaling pathway upon ligand binding, and transduce signals that promote cell death by apoptosis. Other evidence suggests that TNFR-1 has nonapoptotic functions as well, including promoting cell survival and proliferation, mediating tumorigenesis and tumor progression, in concert with nuclear factor-κB (NF-κB), mitogen-activated protein kinase (MAPK), and Akt signaling (Rivas et al., 2008; Schutze et al., 2008) . However, the direct evidence is required to delineate the role of TNFR-1 signaling in fi brosarcoma cells.
In this study we show that TNFR-1 expression on fi brosarcoma is required for the tumor rejection. Interestingly, TNFR-1 does not affect the tumor cell viability, but reduces VEGF production, indicating a novel effect of TNF-α on fi brosarcoma cells. Most importantly, we provide the fi rst evidence for TNFR-1 on tumor cells as a prerequisite in chemotherapy for fi brosarcoma.
RESULTS

TNFR-1 abundance on fi brosarcoma cells correlates with its tumorigenic potential
The impaired TNFR-1 signaling in tumor cells and the malignant tumor progress have been observed in cancer patients (Yoshimura et al., 2003; Dong et al., 2008) . To detect whether TNFR-1 expression on fi brosarcoma cells correlates with their growth, we examined the growth rates and TNFR-1 expression levels of the methylcholanthrene (MCA)-induced primary tumor cells and these cells after passage in immunocompetent mice. The parental FA09 (FA09-0) was weak in terms of tumorigenic potential, only leading to 60% tumor-positive mice 45 days after tumor inoculation (Fig. 1A) . After one passage in BALB/c mice, the tumorigenic potential of these cells (FA09-1) was markedly increased and all mice were tumor bearing 45 days after tumor cell inoculation (Fig. 1A) .
To assess whether TNFR-1 confers fi brosarcoma cells with some growth advantage, we examined the TNFR-1 expression levels on FA09-0 and FA09-1 cells using fl ow cytometry and western blot. As shown in Fig. 1B and 1C , the cell surface expression of TNFR-1 on FA09-1 cells was significantly decreased as compared with that on FA09-0 cells, suggesting TNFR-1 low-expressing fibrosarcoma cells may be selected for tumor growth advantage in vivo.
Establishment of Tnfr1
+ and Tnfr1 -fi brosarcoma cell lines
To further investigate the effect of TNFR-1 on fibrosarcoma cells, we established a TNFR-1 defi cient tumor cell line FB61 induced by MCA in TNFR-1 knockout BALB/c mice (Zhao et al., 2012) . FB61 tumor cells were transfected with a TNFR-1-expressing plasmid as described in materials and methods, resulting in a TNFR-1 competent tumor cell line FB61-R1, with FB61-m as control. TNFR-1 mRNA expression in FB61-R1 or FB61-m cells was shown in Fig. 2A . A 1624-bp band was amplifi ed from FB61-R1 but not FB61-m cells Apart from FB61 fi brosarcoma, the similar results were also obtained from FD99 fi brosarcoma (data not shown).
To explore whether the FB61-R1 tumor growth retardation is due to the reduced survival rate of these cells, FB61-m and FB61-R1 cells were analyzed for cell survival rate at 72 h with or without the stimulation of mouse TNF-α in vitro. As shown in Fig. 3C , TNF-α had little infl uence on the survival rate of FB61-m or FB61-R1 cells. Taken together, these results show that TNFR-1 expression on fi brosarcoma cells leads to the delayed tumor growth in vivo, but does not affect the cell viability in vitro.
Delayed tumor growth of Tnfr1
+ fi brosarcoma cells is also observed in TNFR-1 defi cient mice TNFR-1 is expressed on almost all cell types in wild type mice (Aggarwal, 2003) . Thus besides fibrosarcoma cells, many turing these cells in the presence of recombinant mouse T NF-α for 48 h. The signaling pathway downstream of TNFR-1 was also detected. TNF-α binding TNFR-1 could induce degradation of inhibitor kappa B-alpha (IκBα) in cells, resulting in the release of NF-κB, which then translocates to the nucleus (Cabal- Hierro and Lazo, 2012) . As shown in Fig. 2E , IκBα was only reduced in TNF-α-treated FB61-R1 cells (Fig. 2F ). Similarly, the protein level of nuclear NF-κ B was only increased in T NF-α-treated FB61-R1 cells (Fig. 2F ). These results confi rm that TNFR-1 is successfully reconstructed in fi brosarcoma cell line FB61.
TNFR-1 expression on fi brosarcoma cells leads to the delayed tumor growth
In order to evaluate the effect of TNFR-1 on fi brosarcoma cells in tumor growth, FB61-m and FB61-R1 cells were correspondingly inoculated into the left and right fl anks of BALB/c mice. The tumor growth rate results showed that TNFR-1 expression on fi brosarcoma cells signifi cantly reduced the FB61-R1 tumor 
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& fi brosarcoma cells mediates its effect for angiostasis. VEGF has been shown to play a central role in tumor neovascularization, which is mainly produced by tumor cells (Ferrara et al., 2003) . To investigate whether TNFR-1 activation alters the production of VEGF by fi brosarcoma cells, FB61-R1 and FB61-m cells were stimulated with TNF-α in vitro and the mRNA of other types of cells, especially the tumor stromal cells can respond to TNF-α in this model. The T NFR-1 defi cient mice were then used to exclude the effects of TNFR-1 on stromal cells. FB61-m and FB61-R1 cells were inoculated to the TNFR-1 defi cient mice as described before. We found that the tumor size of FB61-R1 was also signifi cantly s hrunk compared with the FB61-m group in TNFR-1 knockout mice (Fig. 4) . Taken together, these results show that the response of Tnfr1 + fi brosarcoma cells to endogenous TNF-α impairs the tumor growth.
TNFR-1 activation inhibits VEGF production by fi brosarcoma cells
Next, we investigated whether TNFR-1 activation on fi brosarcoma cells impairs tumor angiogenesis. The concentration of h emoglobin in the tumor was quantified to reflect the abundance of blood vessels. As shown in Fig. 5A , the FB61-m tumors had 7.14 ± 1.77 μg/mg hemoglobin, whereas the hemoglobin concentration of FB61-R1 tumors was only 2.13 ± 0.25 μg/mg. Immunostaining using an anti-mouse CD31 monoclonal antibody (mAb) was also performed on sections of these tumors to detect the vasculature intensity. Consistent with the results above, a decreased intensity of CD31 + microvessels was observed in FB61-R1 tumors compared with the FB61-m tumors ( Fig. 5B and 5C ). The fi ndings suggest that TNFR-1 expression on fi brosarcoma cells inhibits tumor-induced angiogenesis. We examined subsequently how TNFR-1 expression on (Fig. 6A) . VEGF concentration from the supernatant of fibrosarcoma cells was also determined using ELISA. As shown in Fig. 6B , VEGF production was signifi cantly inhibited when Tnfr1 + fi brosarcoma cells respond to TNF-α. In summary, the results indicate that TNF-α reacting on Tnfr1 + fi brosarcoma cells inhibits tumor angiogenesis possibly via down-regulation of tumor cell-derived VEGF.
Tnfr1
+ fi brosarcoma is more sensitive to chemotherapy
Chemotherapy is an effective way to treat many types of cancer, and melphalan has been used for cancer treatments since 1966 (Palumbo et al., 2006; Sha et al., 2012) . The correlation of TNFR-1 expression on tumor cells and the chemotherapy effi ciency for fi brosarcoma was further investigated. As shown in Fig. 7A , melphalan treatment resulted in a short delay of tumor growth, but a quick remission of FB61-m tumors. Importantly, when FB61-R1 tumors were treated with melphalan, tumor growth was similarly delayed at fi rst and then completely rejected at 32 days after tumor inoculation (Fig. 7B) . In summary, these data clearly demonstrate that TNFR-1 expression on fi brosarcoma cells inhibits tumor growth, and it largely contributes to the sensitivity of chemotherapy.
DISCUSSION
In this study, the direct effects of TNF-α on fi brosarcoma cells were modeled using cancer cells with or without TNFR-1 expression. TNFR-1 expressing FB61 cells were insensitive to the cytotoxicity of TNF-α in vitro. But VEGF production was reduced in fi brosarcoma cells after TNFR-1 activation. Further in vivo experiments showed that TNFR-1 expression on fi brosarcoma cells retarded tumor growth, and contributed to the sensitivity of chemotherapy. Therefore, our fi nding provides evidence that TNFR-1 expression on fi brosarcoma facilitates tumor rejection in chemotherapy. It suggests that a high TNFR-1 expression on tumor cells could be a favorable indicator of prognosis and TNFR-1 may be an effective target in chemotherapy for some tumor types in the clinic. Fibrosarcoma, originating from mesenchymal cell, is composed of malignant fi broblasts in a collagen background (Coffi n and Alaggio, 2012). It is a malignant cancer with about 15% mortality rate (Orbach et al., 2005; Orbach et al., 2010 ; Coffi n and Alaggio, 2012). TNFR-1 signaling in tumor growth has been largely studied. In other studies, it mainly focused on the direct effect of TNFR-1 on tumor cell survival or apoptosis have also found that various chemotherapeutic agents up-regulate angiogenic VEGF secretion in tumor cells, which had signifi cantly deleterious effect on disease-free survival of patients (Riedel et al., 2004; Ogata et al., 2006; Fan et al., 2008) . Thus combination therapy with anti-inflammatory agent is usually used in clinical trials. Melphalan plus dexamethasone (acts as an anti-infl ammatory agent) is a common conventional chemotherapy for various disorders (Li et al., 2011) . Liver cancer was also effectively treated using a combination of melphalan and bevacizumab (an anti-VEGF antibody) (Voron et al., 2012) . In this study, VEGF production was largely reduced in fi brosarcoma cells with TNFR-1 activation. The reduced VEGF may not just contribute to the angiostasis, but also at least partly, counteract with the side effects of chemotherapy.
In conclusion, this study reveals evidence that TNFR-1 expression on fi brosarcoma cells contributes to the tumor rejection especially during chemotherapy, indicating a novel insight into the therapeutic approach against tumors using TNFR-1-angonist.
MATERIALS AND METHODS
Mice
TNFR-1 knockout and competent mice on BALB/c background were obtained as described previously (Zhao et al., 2012) . All mice were bred in the specifi c pathogen-free barrier facility of Institute of Biophysics, Chinese Academy of Sciences. In all experiments described here, female mice aged 6 -8 weeks were used.
Cell lines
The Tnfr1 -fi brosarcoma FB61 cells and the Tnfr -cell line FD99 were chose for the experiments (Zhao et al., 2012) . Plasmid pLPC-TNFR-1 was transfected into the cells, and the transfectants were screened for TNFR-1 positive cells. As a control, cells were also transfected with the empty vector pLPC, resulting in the mock-transfected cell line. (Edelblum et al., 2008; Rauert et al., 2011) . In this study, we fi rstly demonstrated that TNF-α had little direct effect on fi brosarcoma cell growth, but other multiple effects on fi brosarcoma cells. Our data showed that TNF-α acting on Tnfr1 + fi brosarcoma cells down-regulated VEGF production, and induced the angiostasis. In addition, it also up-regulated MHC class I expression on FB61-R cells, which may play a signifi cant role for better T cell recognition/elimination in this tumor model (Qin and Blankenstein, 2000) . In particular, the enhanced NF-κB activity in FB61-R1 cells may contribute to the tumor cell immunogenicity, for NF-κB families have emerged as critical regulators for cell immunogenic activities (Ouaaz et al., 2002) . Furthermore, TNF-related apoptosis-inducing ligand (TRAIL) enables immune effectors to detect and lyse tumor cells (Green et al., 2009; Kepp et al., 2009a; Kepp et al., 2009b) , demonstrating a capacity of TNFR-1 in stimulating immunologic tumor cell death. Considering the complex cell-cell interactions in the tumor microenvironment in vivo, it is possible that except for endogenous TNF-α, other cytokines may also be involved in the tumor growth defi ciency of FB61-R1 (Ruegg et al., 1998; Bauer et al., 2009) . Therefore, the exact mechanisms of how Tnfr1 + fi brosarcoma cells were more effi ciently rejected are still required further investigation. Although surgery should still remain the mainstay of fi brosarcoma treatment, chemotherapy has been reported to be fairly effective especially in infantile fi brosarcoma (IFS) (Orbach et al., 2010) . Melphalan is an alkylating agent with broadspectrum activity in a variety of malignancies that creates interand intra-strand DNA cross-links. It has been used for treating cancer patients for decades (Palumbo et al., 2006) . However, a variety of side effects come along with chemotherapy treatments including system infl ammation induction. Several studies have shown that systemic chemotherapy treatment to cancer patients often stimulates the production of interleukin-1β (IL-1β), TNF-α, and IL-6 (Wood et al., 2006a, 2006b) . Researchers 
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& was detected with the following designed primer pairs: TNFR-1 (sense) 5′-GGAATTCAAGCTTGGCCGGACATGGGTCT-3′ and (antisense) 5′-GGAATTCCCGCGGCCTGTCTTTGGCACCCT-3′; VEGF (sense) 5′-CTCCACCATGCCAAG-3′ and (antisense) 5′-GCTGGTAGACATC-CAT-3′; and β-actin (sense) 5′-GAAGTGTGACGTTGACATCCGTA-3′ and (antisense) 5′-CTCAGGAGGAGCAATGATCTTGA -3′.
Immunostaining and immunoblotting
For histological staining of tumor tissues, tumors were embedded in optimal cutting temperature (OCT) compound, frozen, and cut with a cryostat. Tumor tissues were stained with a rat anti-mouse CD31 mAb (BD biosciences), with an isotype-matched control mAb (BD biosciences) as control. Pictures were taken using an Olympus BX51 microscope. Microvessel density was measured according to Weidner's method (Lu et al., 2009 ). Nuclear and cytoplasmic protein was extracted using a nuclear and cytoplasmic protein extraction kit (Beyotime). Primary antibodies used were as follows: TNFR-1 (1:1000; Abcam), NF-κB (1:1000; Cell Signaling Technology), p-IκBα (1:1000; Cell Signaling Technology), and β-actin (1:8000; Sigma-Aldrich). HRP-conjugated goat anti-mouse or goat anti-rabbit IgG (Thermo) were used as secondary antibodies.
Statistical analysis
Statistical analysis was performed using a two-tailed Student's t test. Statistically signifi cant differences are indicated as follows: *, P ＜0.05; **, P < 0.01.
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All institutional and national guidelines for the care and use of laboratory animals were followed. To investigate the role of TNFR-1 in tumor cell sensitivity to chemotherapy, mice were given melphalan (7.5 mg/kg) by intraperitoneal (i.p.) injection when tumor size reached 6-8 mm.
Flow cytometry
Tumor cells were harvested to form single cell suspension. Cell surface TNFR-1 expression was determined using an anti-mouse TNFR-1 antibody (Ab) (BioLegend). To confi rm TNFR-1 function, FB61-m and FB61-R1 cells were cultured with or without 20 ng/mL recombinant murine TNF-α (Peprotech) for 48 h. These cells were then stained for MHC class I expression with an anti-H2-K d mAb (BD Pharmingen) or an isotype-matched control mAb.
Cell survival rate
FB61-R1 and FB61-m cells were seeded into 96-well plates at 3 × 10 3 per well in 200 μL RPMI 1640 with or without the addition of 20 ng/mL TNF-α. After 72 h of culturing, cell viability was determined using a CCK-8 kit (Beyotime). Absorbance values were measured at 450 nm on a microplate spectrophotometer (Bio-Rad Laboratories).
Soluble TNFR-1 (sTNFR-1) and VEGF concentration detection
To detect sTNFR-1 production, the supernatant of FB61-m or FB61-R1 cells was collected after a 48-h culture. The concentration of sTNFR-1 in the cell supernatant was determined using an ELISA kit (R&D Systems, Minneapolis, MN, USA), which detected both free and TNFbinding forms of sTNFR-1. VEGF production in the tumor tissues was determined using an ELISA kit according to the manufacturer's instructions (eBioscience).
Analysis of hemoglobin content in tumors
Hemoglobin content in isolated tumors was estimated as described previously (Lu et al., 2009) . In brief, tumors were isolated, minced, and homogenized. The hemoglobin in the tumor tissues was then extracted. One milliliter (mL) of the sample was added to 5 mL of Drabkin's solution. Readings were obtained at 540 nm using a spectrophotometer. The concentration of hemoglobin in different tumors was expressed as hemoglobin content per microgram of tumor tissue.
Real time (RT)-PCR
RNA was extracted using the TRIZOL reagent kit per the manufacturer's instructions (Molecular Research Center). Gene expression
